MELISSA RUDD: Open Payments
NPI 1124131776 · LUTZ, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,226 in 60 payments from 12 companies in 2025. Trend: 2023 $0 · 2024 $114 · 2025 $1,226
Food & beverage: $1,226
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 15 | $192 |
| Otsuka America Pharmaceutical, Inc. | 15 | $166 |
| E.R. Squibb & Sons, L.L.C. | 4 | $164 |
| Neurocrine BioSciences, Inc. | 7 | $160 |
| Gilead Sciences, Inc. | 1 | $131 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 5 | $116 |
| Alkermes, Inc. | 4 | $70 |
| Vanda Pharmaceuticals Inc. | 2 | $55 |
| Axsome Therapeutics, Inc. | 2 | $52 |
| Merck Sharp & Dohme LLC | 2 | $48 |
Products named: REXULTI, COBENFY, INGREZZA, CAPLYTA, UZEDY, AUSTEDO XR, FANAPT, ARISTADA.
Industry payments across FL — which companies pay providers there.
